SAHA, a broad spectrum HDAC inhibitor, reduced fibroblast induced migration of monocytes, suggesting that HDACs support vascular inflammation and that HDAC inhibitors can be anti-inflammatory drugs in treating PAH. Here, HDAC9 is linked to pulmonary arterial hypertension.